🇺🇸
SHANGHAI, Aug. 12, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the Investigational New Drug (IND) application for AK0406 injection, the company’s first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has…
Source: prnewswire
Country: United States